Related Experiment Video
Updated: Jan 19, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity
Justine Badée1, Nahong Qiu2, Abby C Collier3
1Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida at Lake Nona, Orlando, Florida, USA.
Insights
Understanding the postnatal development of hepatic UDP-glucuronosyltransferase (UGT) enzymes is crucial for pediatric drug dosing. This study characterized UGT isoform maturation, revealing significant age-dependent changes in glucuronidation activity essential for pharmacokinetic predictions.
Area of Science:
- Pharmacology
- Biochemistry
- Pediatrics
Background:
- Accurate prediction of pediatric drug pharmacokinetics requires understanding hepatic UDP-glucuronosyltransferase (UGT) enzyme development.
- The maturation rates of specific hepatic UGT isoforms represent a significant knowledge gap in pediatric drug metabolism.
Purpose of the Study:
- To establish age-associated changes in the glucuronidation activity of 10 major human hepatic UGT isoforms.
- To characterize the postnatal ontogeny profiles of these UGT enzymes for improved drug disposition prediction in children.
Main Methods:
- Human liver microsomes from pediatric and adult donors were used.
- Activity rates of 10 UGT isoforms were assessed using 19 in vitro UGT probe substrates and drugs.
- Correlations in glucuronidation activities were analyzed to establish ontogeny.
Main Results:
- Postnatal development of hepatic UGTs is isoform-dependent.
- Maximal adult activity was reached at different ages, from within a month to adolescence.
- Ontogeny was established for UGT1A1, UGT1A4, UGT2B7, UGT2B10, and UGT2B15.
Conclusions:
- This study provides extensive characterization of hepatic UGT ontogeny profiles.
- These findings are instrumental for predicting drug disposition using in vitro-in vivo extrapolation.
- Results aid in verifying pharmacokinetic predictions in pediatric patients via physiologically based pharmacokinetic modeling.
Abstract:
An understanding of the postnatal development of hepatic UDP-glucuronosyltransferase (UGT) enzymes is required for accurate prediction of the age-dependent changes in pharmacokinetics of many drugs used in children. However, the maturation rate of hepatic UGT isoforms remains a major knowledge gap. This study aimed to establish the age-associated changes in glucuronidation activity of 10 major hepatic UGT isoforms in humans, namely, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17. Human liver microsomes from pediatric and adult donors were incubated under optimized incubation conditions to assess the activity rates of hepatic UGT isoforms using a panel of 19 in vitro UGT probe substrates and clinically used drugs. Statistically strong correlations of glucuronidation activities allowed the ontogeny of UGT1A1, UGT1A4, UGT2B7, UGT2B10, and UGT2B15 to be established using multiple selective UGT substrates and matched human liver microsome samples. The postnatal development of hepatic UGTs is isoform-dependent using either individual or cross-correlated selective isoform substrates. Maximal adult activity was reached at different times ranging from within a month (UGT1A1, UGT2B4, UGT2B7, UGT2B10, and UGT2B15), during infancy (UGT1A3, UGT1A4, and UGT1A9), to adolescence (UGT1A6 and UGT2B17). This study provides an extensive characterization of the postnatal ontogeny profiles of hepatic UGT enzymes that are instrumental for predicting drug disposition via in vitro-in vivo extrapolation algorithms and verifying pharmacokinetic predictions against in vivo observations via pediatric physiologically based pharmacokinetic modeling in pediatric patients.
Related Concept Videos
07:10Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
11:44Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells
09:52Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
08:54Functional Human Liver Preservation and Recovery by Means of Subnormothermic Machine Perfusion
03:42Isolation of Marginating Hepatic Leukocytes from a Mouse Liver
04:46Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery

